This study from Taiwan retrospectively examined 30 patients with unresectable CC who were treated with PBT to a total dose of 72.6 GyRBE. The 1-year local control, regional control, and distant metastases-free rates were 88%, 86%, and 68%, respectively. The median overall survival and progression-free survival were 19.3 and 10.4 months.

The most common acute toxicity was acute skin reactions which were rarely severe (grade III: 7% of patients). Three and 2 patients had grade III-IV toxicities and radiation-induced liver disease. There were no deaths caused by PBT or concurrent chemotherapy. The authors concluded that PBT is clinically useful in patients with unresectable CC.